Related Experiment Video
Updated: Nov 10, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Mild cognitive impairment and major depressive disorder are associated with molecular senescence abnormalities in
Breno S Diniz1,2,3, Erica M Vieira1, Ana Paula Mendes-Silva1
1Platform for Peripheral Biomarkers Discovery Centre for Addiction and Mental Health (CAMH) Campbell Family Mental Health Research Institute Toronto Ontario Canada.
Introduction:
The biological mechanisms linking mild cognitive impairment (MCI) and major depressive disorder are not well understood. We investigated whether molecular senescence changes in older adults are associated with a history of major depressive disorder (MDD) or MCI.
Methods:
We included 371 participants: 167 with MCI; 62 cognitively normal with a history of MDD; 97 with MDD+MCI; and 45 cognitively unimpaired (CU) without a history of MDD. The candidate Senescence-Associated Secretory Phenotype (SASP) biomarkers were measured in the plasma using a customized LUMINEX assay.
Results:
The MDD+MCI group had a higher SASP index than the other groups (P < .001). A higher SASP index was significantly associated with worse global cognitive performance, executive dysfunction, slower processing speed, and episodic memory deficits.
Discussion:
Our study suggests that increased molecular changes are associated with cognitive impairment in older adults with MDD and indicate that accelerated biological aging is an underlying feature of MDD.
Insights
Older adults with major depressive disorder (MDD) and mild cognitive impairment (MCI) show increased molecular senescence. This suggests accelerated biological aging may underlie MDD and cognitive decline.
Area of Science:
- Gerontology
- Neuroscience
- Psychiatry
Background:
- The relationship between mild cognitive impairment (MCI) and major depressive disorder (MDD) is not fully understood.
- Investigating molecular senescence in older adults with a history of MDD or MCI.
Purpose of the Study:
- To determine if molecular senescence changes are associated with MDD or MCI in older adults.
- To explore the link between senescence markers and cognitive function.
Main Methods:
- 371 participants were analyzed: MCI, cognitively normal with MDD history, MDD+MCI, and cognitively unimpaired controls.
- Senescence-Associated Secretory Phenotype (SASP) biomarkers were measured in plasma using a customized LUMINEX assay.
Main Results:
- The MDD+MCI group exhibited a significantly higher SASP index compared to other groups (P < .001).
- Elevated SASP index correlated with poorer global cognitive performance, executive dysfunction, slower processing speed, and episodic memory deficits.
Conclusions:
- Increased molecular senescence is linked to cognitive impairment in older adults with MDD.
- Accelerated biological aging appears to be a key feature underlying MDD.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Cognitive Development During Adulthood
Dementia
The progression of dementia is generally gradual....
Aging
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Long-term Depression
Calcium Ion Concentration Mechanism
If over...
Depression: Overview

